Literature DB >> 25534729

Involvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis.

Quanxin Long1, Qinglin Du2, Tiwei Fu2, Karl Drlica3, Xilin Zhao4, Jianping Xie5.   

Abstract

The absence of the Holliday-junction Ruv resolvase of Mycobacterium smegmatis increased the bacteriostatic and bactericidal activities of the fluoroquinolone moxifloxacin, an important antituberculosis agent. The treatment of ruvAB-deficient cells with thiourea and 2,2'-bipyridyl lowered moxifloxacin lethality to wild-type levels, indicating that the absence of ruvAB stimulates a lethal pathway involving reactive oxygen species. A hexapeptide that traps the Holliday junction substrate of RuvAB potentiated moxifloxacin-mediated lethality, supporting the development of small-molecule enhancers for moxifloxacin activity against mycobacteria.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25534729      PMCID： PMC4325773          DOI： 10.1128/AAC.04434-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Holliday junction processing in bacteria: insights from the evolutionary conservation of RuvABC, RecG, and RusA.

Authors:  G J Sharples; S M Ingleston; R G Lloyd
Journal:  J Bacteriol       Date:  1999-09       Impact factor: 3.490

2.  Salvage therapy for multidrug-resistant tuberculosis.

Authors:  K J Seung; M C Becerra; S S Atwood; F Alcántara; C A Bonilla; C D Mitnick
Journal:  Clin Microbiol Infect       Date:  2013-08-30       Impact factor: 8.067

3.  Transposon site hybridization in Mycobacterium tuberculosis.

Authors:  Jeffrey P Murry; Christopher M Sassetti; James M Lane; Zhifang Xie; Eric J Rubin
Journal:  Methods Mol Biol       Date:  2008

4.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.

Authors:  Banurekha V Velayutham; Iliayas S Allaudeen; Gomathi N Sivaramakrishnan; Venkatesan Perumal; Dina Nair; Ponnuraja Chinnaiyan; Paul K Paramasivam; Baskaran Dhanaraj; Ramesh K Santhanakrishnan; Gangadevi P Navaneethapandian; Makesh K Marimuthu; Vanaja Kumar; Chandrasekaran Kandasamy; Kalaiselvi Dharuman; Thiruvalluvan Elangovan; Meenakshi Narasimhan; Sridhar Rathinam; Gangadharan Vadivelu; Prabhakaran Rathinam; Chandrasekar Chockalingam; Lavanya Jayabal; Soumya Swaminathan; Jawahar M Shaheed
Journal:  Clin Infect Dis       Date:  2014-07-14       Impact factor: 9.079

6.  Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.

Authors:  R T Chow; T J Dougherty; H S Fraimow; E Y Bellin; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

7.  Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.

Authors:  Muhammad Malik; Tao Lu; Xilin Zhao; Anubha Singh; Christopher M Hattan; John Domagala; Robert Kerns; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  A common mechanism of cellular death induced by bactericidal antibiotics.

Authors:  Michael A Kohanski; Daniel J Dwyer; Boris Hayete; Carolyn A Lawrence; James J Collins
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

9.  The RuvAB branch migration complex can displace topoisomerase IV.quinolone.DNA ternary complexes.

Authors:  Molly E Shea; Hiroshi Hiasa
Journal:  J Biol Chem       Date:  2003-09-17       Impact factor: 5.157

10.  DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.

Authors:  C R Chen; M Malik; M Snyder; K Drlica
Journal:  J Mol Biol       Date:  1996-05-17       Impact factor: 5.469
View more
  6 in total

Review 1.  Antibiotic efficacy-context matters.

Authors:  Jason H Yang; Sarah C Bening; James J Collins
Journal:  Curr Opin Microbiol       Date:  2017-10-16       Impact factor: 7.934

2.  Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.

Authors:  M J Ferrándiz; A J Martín-Galiano; C Arnanz; T Zimmerman; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

3.  Proteasome Accessory Factor C (pafC) Is a novel gene Involved in Mycobacterium Intrinsic Resistance to broad-spectrum antibiotics--Fluoroquinolones.

Authors:  Qiming Li; Longxiang Xie; Quanxin Long; Jinxiao Mao; Hui Li; Mingliang Zhou; Jianping Xie
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

Review 4.  Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement.

Authors:  Amit Singh; Xilin Zhao; Karl Drlica
Journal:  Front Cell Infect Microbiol       Date:  2022-09-29       Impact factor: 6.073

5.  Eagle Effect in Nonreplicating Persister Mycobacteria.

Authors:  Mu-Lu Wu; Jasmie Tan; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

6.  Resveratrol Antagonizes Antimicrobial Lethality and Stimulates Recovery of Bacterial Mutants.

Authors:  Yuanli Liu; Jinan Zhou; Yilin Qu; Xinguang Yang; Guojing Shi; Xiuhong Wang; Yuzhi Hong; Karl Drlica; Xilin Zhao
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.